JPET Medipak's UVLI- Bags blind and protect

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connolly, K.
Right arrow Articles by Moore, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connolly, K.
Right arrow Articles by Moore, P. A.

Vol. 298, Issue 1, 25-33, July 2001

In Vivo Inhibition of Fas Ligand-Mediated Killing by TR6, a Fas Ligand Decoy Receptor

Kevin Connolly, Yun Hee Cho, Roxanne Duan, James Fikes, Theresa Gregorio, David W. LaFleur, Zebedee Okoye, Theodora W. Salcedo, Gemma Santiago, Stephen Ullrich, Ping Wei, Kathleen Windle, Eling Wong, Xiao-Tao Yao, Ya-Qin Zhang, Grace Zheng and Paul A. Moore

Human Genome Sciences Inc., Rockville, Maryland

TR6, a member of the tumor necrosis factor (TNF) receptor superfamily, has recently been shown to bind to Fas ligand (FasL) and inhibit FasL-mediated cell killing in vitro. In the current study, we demonstrate that TR6 can block the lethal activity of FasL in multiple in vitro systems, and extend this finding to an in vivo model of hepatitis. The binding of human TR6 to human FasL was verified with BIAcore chip technology. Human primary hepatocytes, HT-29 cells and Jurkat cells were assayed for viability to demonstrate TR6 inhibition of FasL-mediated cytotoxicity in vitro. Human TR6 was also shown to cross-react with membrane-bound mouse FasL, since the in vitro cytotoxic activity of L929 cells transfected with murine FasL was inhibited in the presence of human TR6. In vivo, FasL-induced acute, lethal, fulminant hepatic apoptosis resulting in death within 2 h of intravenous injection into Fas+ mice, but not Fas- MRL/lpr mice. Pretreatment of mice with TR6 blocked FasL-induced mortality, presumably by attenuating FasL-induced hepatic apoptosis. Thus, in both in vitro and in vivo systems, TR6 acts as a functional FasL decoy receptor and may be clinically useful in the treatment of hepatitis and other diseases associated with FasL-mediated tissue injury.

0022-3565/01/2981-0025$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Immunol.Home page
T.-L. Hsu, Y.-Y. Wu, Y.-C. Chang, C.-Y. Yang, M.-Z. Lai, W. B. Su, and S.-L. Hsieh
Attenuation of Th1 Response in Decoy Receptor 3 Transgenic Mice
J. Immunol., October 15, 2005; 175(8): 5135 - 5145.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Shi, J. Mao, G. Yu, J. Zhang, and J. Wu
Tumor Vaccine Based on Cell Surface Expression of DcR3/TR6
J. Immunol., April 15, 2005; 174(8): 4727 - 4735.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-R. Yang, S.-L. Hsieh, C.-M. Teng, F.-M. Ho, W.-L. Su, and W.-W. Lin
Soluble Decoy Receptor 3 Induces Angiogenesis by Neutralization of TL1A, a Cytokine Belonging to Tumor Necrosis Factor Superfamily and Exhibiting Angiostatic Action
Cancer Res., February 1, 2004; 64(3): 1122 - 1129.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. Kim, W. J. McAuliffe, L. S. Zaritskaya, P. A. Moore, L. Zhang, and B. Nardelli
Selective Induction of Tumor Necrosis Receptor Factor 6/Decoy Receptor 3 Release by Bacterial Antigens in Human Monocytes and Myeloid Dendritic Cells
Infect. Immun., January 1, 2004; 72(1): 89 - 93.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Waxman and P. S. Schwartz
Harnessing Apoptosis for Improved Anticancer Gene Therapy
Cancer Res., December 15, 2003; 63(24): 8563 - 8572.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. J. Wroblewski, C. McCloud, K. Davis, J. Manetta, R. Micanovic, and D. R. Witcher
Pharmacokinetics, Metabolic Stability, and Subcutaneous Bioavailability of a Genetically Engineered Analog of DcR3, FLINT [DcR3(R218Q)], in Cynomolgus Monkeys and Mice
Drug Metab. Dispos., April 1, 2003; 31(4): 502 - 507.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Wan, J. Zhang, H. Luo, G. Shi, E. Kapnik, S. Kim, P. Kanakaraj, and J. Wu
A TNF Family Member LIGHT Transduces Costimulatory Signals into Human T Cells
J. Immunol., December 15, 2002; 169(12): 6813 - 6821.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T.-L. Hsu, Y.-C. Chang, S.-J. Chen, Y.-J. Liu, A. W. Chiu, C.-C. Chio, L. Chen, and S.-L. Hsieh
Modulation of Dendritic Cell Differentiation and Maturation by Decoy Receptor 3
J. Immunol., May 15, 2002; 168(10): 4846 - 4853.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.